Dashboards

Near Real-Time Monitoring

P95 developed this in the IMI ADVANCE project. We are now able to monitor near real-time benefits and risks of vaccines in the post-marketing stage. We were responsible for connecting to various data sources, data cleaning and quality assurance, data modelling and simulation, data visualisation, web application development and secure data access. More information: Dashboard on simulated data Dashboard with real data

VEMC

P95 developed the Vaccine Effectiveness Misclassification (VEMC) application to perform calculations to quantify and adjust for the effect of exposure misclassification using novel statistical methods developed in the IMI ADVANCE project.

More information:
https://journals.plos.org/plosone/article/related?id=10.1371/journal.pone.0199180

InterR

P95 developed this online calculation tool during the IMI ADVANCE project to allow researchers to calculate and adjust various interrelated indices (sensitivity, specificity, etc.) connected to epidemiologic research.

ESSA

P95 developed the Electronic Study Support Application as a one-stop data upload and data quality assessment application for database custodians to use with their seasonal influenza data.

P95 has also been contracted to develop various web applications for top pharma clients and international partners (such as WHO, CEPI, etc.) on vaccine coverage, systematic literature review data and other topics.

Publications

Alexandridou, M., T. Cattaert and T. Verstraeten (2021). “Estimation of Risk of Death Attributable to Acute Gastroenteritis Not Caused by Clostridioides difficile Infection Among Hospitalized Adults in England.” Clin Epidemiol 13: 309-315. 10.2147/CLEP.S296516

Baay, M., B. Lina, A. Fontanet, A. Marchant, M. Saville, P. Sabot, J. Vandeputte and P. Neels (2021). “Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic.” Biologicals 69: 76-82. 10.1016/j.biologicals.2020.11.003

Baay, M. and P. Neels (2021). “Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development.” Front Immunol 12: 658783. 10.3389/fimmu.2021.658783

Biccler, J., K. Bollaerts, P. Vora, E. Sole, L. A. G. Rodriguez, A. Lanas, R. E. Langley and M. S. Gabarró (2021). “Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK – Results from micro-simulation model.” Int J Cardiol Heart Vasc 36: 100851. 10.1016/j.ijcha.2021.100851

Click here for the full list (updated September 2021)